Market Research Logo

Johnson & Johnson - Product Pipeline Review - 2016

Johnson & Johnson - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Johnson & Johnson - Product Pipeline Review - 2016’, provides an overview of the Johnson & Johnson’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Johnson & Johnson, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Johnson & Johnson
  • The report provides overview of Johnson & Johnson including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Johnson & Johnson’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Johnson & Johnson’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Johnson & Johnson’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Johnson & Johnson
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Johnson & Johnson’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Johnson & Johnson Snapshot
Johnson & Johnson Overview
Key Information
Key Facts
Johnson & Johnson - Research and Development Overview
Key Therapeutic Areas
Johnson & Johnson - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Johnson & Johnson - Pipeline Products Glance
Johnson & Johnson - Late Stage Pipeline Products
Johnson & Johnson - Clinical Stage Pipeline Products
Johnson & Johnson - Early Stage Pipeline Products
Johnson & Johnson - Unknown Stage Pipeline Products
Johnson & Johnson - Drug Profiles
(canagliflozin + metformin hydrochloride XR)
bedaquiline fumarate
daratumumab
ustekinumab
bortezomib
golimumab
tipifarnib
(cobicistat + darunavir + emtricitabine + tenofovir alafenamide)
(naproxen sodium + sumatriptan succinate)
abiraterone acetate
canagliflozin
esketamine hydrochloride
fulranumab
guselkumab
imetelstat sodium
infliximab
JNJ-56021927
rivaroxaban
sirukumab
tapentadol hydrochloride IR
trabectedin
JNJ-54861911
(AL-335 + odalasvir + simeprevir)
AL-335
ALS-8176
Cell Therapy for HIV-1 Infection
CNTO-3157
CNTO-6785
erdafitinib
JNJ-39393406
JNJ-40411813
JNJ-42039556
JNJ-42847922
JNJ-49095397
JNJ-53718678
JNJ-56022473
JNJ-56914845
JNJ-872
odalasvir
ORM-12741
quisinostat hydrochloride
rilpivirine
siltuximab
sovaprevir
TMC-310911
toreforant tartrate
CNTO-2476
COVA-322
telaprevir
Vaccine for Prostate Cancer
ACH-3422
AL-794
ALS-8112
CNTO-7160
EVT-100 Series
EVT-103
JNJ-18038683
JNJ-38877618
JNJ-42721458
JNJ-47910382
JNJ-49122944
JNJ-54175446
JNJ-55375515
JNJ-55920839
JNJ-56136379
JNJ-61610588
JNJ-64052781
JNJ-757
JNJ-809
NVR-3778
RV-1162
RV-1729
TOP-1288
Small Molecules for Rhinovirus Infections
Small Molecules to Inhibit Viral RNA Polymerase for RSV Infections
AL-516
CNTO-530
COVA-208
COVA-420
COVA-493
COVA-494
DiTU
flubendazole
Gene Therapy for Arteriosclerosis and Endothelial Dysfunction
JNJ-26070109
JNJ-26993135
JNJ-28307474
JNJ-28312141
JNJ-28610244
JNJ-31020028
JNJ-35815208
JNJ-375
JNJ-39729209
JNJ-39933673
JNJ-40279486
JNJ-40413269
JNJ-41477670
JNJ-42314415
JNJ-42905343
JNJ-46778212
JNJ-47965567
JNJ-5234801
JNJ-54416076
Monoclonal Antibodies to Inhibit TGF-beta 1 for Fibrosis
Monoclonal Antibody for Autoimmune Diseases
Nucleozin
Recombinant Peptides to Block Kv1.3 Channel for Autoimmune Diseases
Recombinant Protein-1 for Undisclosed Indication
Recombinant Protein-2 for Undisclosed Indication
Recombinant Proteins for Inflammatory and Autoimmune Diseases
RV-1088
S-961
Small Molecule to Inhibit Capsid Protein for Hepatitis B
Small Molecule to Inhibit Endothelial Lipase for Hypercholesterolemia
Small Molecule to Inhibit FLT3 for AML
Small Molecule to Inhibit PDE10A for Schizophrenia
Small Molecule to Inhibit Stearoyl-CoA Desaturase-1 for Obesity
Small Molecules to Antagonize P2X7 for Central Nervous System
Small Molecules to Inhibit FMS for Rheumatoid Arthritis
Stem Cell Therapy for Type 1 and Type 2 Diabetes
VE-202
ALS-2135
Cellular Immunotherapy for Solid Tumors
Drugs for Cancer
Drugs for Prostate Cancer
influenza vaccine
LCTA-949
Peptides to Inhibit Ion Channel for Chronic Pain
Recombinant Protein for Inflammatory Bowel Diseases
Small Molecule to Inhibit cccDNA for Hepatitis B
Small Molecule to Inhibit Kinase for Autoimmune Diseases
Small Molecules for Central Nervous System Disorders
Small Molecules for Hepatitis B
Small Molecules for Lymphoma
Small Molecules to Antagonize Androgen Receptor for Castration-Resistant Prostate Cancer
Small Molecules to Antagonize CCR2 for Type II Diabetes
Small Molecules to Block Cav2.2 Channel for Chronic Pain
TMC-207 Back Up
VX-353
Biologics for Undisclosed Indication
JNJ-40346527
RV-6153
Johnson & Johnson - Pipeline Analysis
Johnson & Johnson - Pipeline Products by Target
Johnson & Johnson - Pipeline Products by Route of Administration
Johnson & Johnson - Pipeline Products by Molecule Type
Johnson & Johnson - Pipeline Products by Mechanism of Action
Johnson & Johnson - Recent Pipeline Updates
Johnson & Johnson - Dormant Projects
Johnson & Johnson - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Johnson & Johnson - Company Statement
Johnson & Johnson - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Johnson & Johnson, Key Information
Johnson & Johnson, Key Facts
Johnson & Johnson - Pipeline by Indication, 2016
Johnson & Johnson - Pipeline by Stage of Development, 2016
Johnson & Johnson - Monotherapy Products in Pipeline, 2016
Johnson & Johnson - Combination Treatment Modalities in Pipeline, 2016
Johnson & Johnson - Partnered Products in Pipeline, 2016
Johnson & Johnson - Partnered Products/ Combination Treatment Modalities, 2016
Johnson & Johnson - Out-Licensed Products in Pipeline, 2016
Johnson & Johnson - Out-Licensed Products/ Combination Treatment Modalities, 2016
Johnson & Johnson - Pre-Registration, 2016
Johnson & Johnson - Filing rejected/Withdrawn, 2016
Johnson & Johnson - Phase III, 2016
Johnson & Johnson - Phase II, 2016
Johnson & Johnson - Phase I, 2016
Johnson & Johnson - IND/CTA Filed, 2016
Johnson & Johnson - Preclinical, 2016
Johnson & Johnson - Discovery, 2016
Johnson & Johnson - Unknown, 2016
Johnson & Johnson - Pipeline by Target, 2016
Johnson & Johnson - Pipeline by Route of Administration, 2016
Johnson & Johnson - Pipeline by Molecule Type, 2016
Johnson & Johnson - Pipeline Products by Mechanism of Action, 2016
Johnson & Johnson - Recent Pipeline Updates, 2016
Johnson & Johnson - Dormant Developmental Projects,2016
Johnson & Johnson - Discontinued Pipeline Products, 2016
Johnson & Johnson, Subsidiaries
List of Figures
Johnson & Johnson - Pipeline by Top 10 Indication, 2016
Johnson & Johnson - Pipeline by Stage of Development, 2016
Johnson & Johnson - Monotherapy Products in Pipeline, 2016
Johnson & Johnson - Combination Treatment Modalities in Pipeline, 2016
Johnson & Johnson - Partnered Products in Pipeline, 2016
Johnson & Johnson - Out-Licensed Products in Pipeline, 2016
Johnson & Johnson - Pipeline by Top 10 Target, 2016
Johnson & Johnson - Pipeline by Top 10 Route of Administration, 2016
Johnson & Johnson - Pipeline by Top 10 Molecule Type, 2016
Johnson & Johnson - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report